Paul Doyle has taken up the role of Chief Scientific Officer at Concept Life Sciences. The news of his new role coincides with the news that the Concept Life Sciences Group has embarked upon a multi-million pound investment drive, comprising a comprehensive expansion and rebranding programme, to give its international client base a world class integrated service.
Paul, who was previously COO at Peakdale which was acquired by Concept Life Sciences in 2014, has successfully led Concept Life Sciences through an aggressive growth phase over the past two years. He combines sound business acumen with an impressive scientific record having authored over 50 peer reviewed papers and, most recently, co-edited a Royal Society of Chemistry two-volume set on Synthetic Methods in Drug Discovery.
Paul, a bio-organic chemistry DPhil, began his career at the Wellcome Foundation working across a wide variety of discovery programmes. Following the Glaxo merger Paul left Wellcome to establish one of the UK’s first CROs, Biofocus. Following an AIM listing Biofocus was acquired, in 2005, by Galapagos NV, and subsequently acquired by Charles River in 2014. Paul then joined Peakdale, as Technical Director, in 2008 and was promoted to COO in 2010; maintaining that post following the Concept Life Sciences’ acquisition.
Michael Fort, Concept’s Executive Chairman explains “We are delighted that Paul will be acting as our Chief Scientific Officer at Concept Life Sciences. He has done a sterling job at leading us through our ambitious growth programme over the last two years and we look forward to him helping drive our exciting expansion plans during 2017”.